MedKoo Cat#: 465574 | Name: QL-X-138

Description:

WARNING: This product is for research use only, not for human or veterinary use.

QL-X-138 is a BTK and MNK inhibitor. QL-X-138 was found to inhibit BTK, MNK1, and MNK2 with IC50’s of 9.4, 107.4, and 26 nM, respectively. QL-X-138 exhibited good kinase selectivity with a score of 0.01, despite JAK3 inhibition with an IC50 of 55.7 nM. QL-X-138 exhibited GI50 values ranging from submicromolar to low micromolar levels against a panel of cancer cell lines.

Chemical Structure

QL-X-138
QL-X-138
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465574

Name: QL-X-138

CAS#: unknown

Chemical Formula: C25H19N5O2

Exact Mass: 421.1539

Molecular Weight: 421.46

Elemental Analysis: C, 71.25; H, 4.54; N, 16.62; O, 7.59

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
QL-X-138; QLX-138; QL X-138; QL-X138; QL-X 138; QLX138; QL X 138;
IUPAC/Chemical Name
N-(2-methyl-5-(2-oxo-9-(1H-pyrazol-4-yl)benzo[h][1,6]naphthyridin-1(2H)-yl)phenyl)acrylamide
InChi Key
JMVDIGHUQAXWIE-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H19N5O2/c1-3-23(31)29-22-11-19(7-4-15(22)2)30-24(32)9-6-17-12-26-21-8-5-16(10-20(21)25(17)30)18-13-27-28-14-18/h3-14H,1H2,2H3,(H,27,28)(H,29,31)
SMILES Code
CC1=CC=C(C=C1NC(C=C)=O)N(C2=C(C=C3)C=NC4=CC=C(C5=CNN=C5)C=C42)C3=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 421.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dong H, Li X, Cai M, Zhang C, Mao W, Wang Y, Xu Q, Chen M, Wang L, Huang X. Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension. Aging (Albany NY). 2021 May 18;13(10):14234-14257. doi: 10.18632/aging.203040. Epub 2021 May 18. PMID: 34016786; PMCID: PMC8202883. 2: Taguchi YH, Turki T. A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction. PLoS One. 2020 Sep 11;15(9):e0238907. doi: 10.1371/journal.pone.0238907. PMID: 32915876; PMCID: PMC7485840. 3: Wang B, Deng Y, Chen Y, Yu K, Wang A, Liang Q, Wang W, Chen C, Wu H, Hu C, Miao W, Hur W, Wang W, Hu Z, Weisberg EL, Wang J, Ren T, Wang Y, Gray NS, Liu Q, Liu J. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. Eur J Med Chem. 2017 Sep 8;137:545-557. doi: 10.1016/j.ejmech.2017.06.016. Epub 2017 Jun 9. PMID: 28628824. 4: Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13. PMID: 26165234; PMCID: PMC4987129.